Zymeworks (NASDAQ:ZYME) Board Approves Stock Buyback Plan

Zymeworks (NASDAQ:ZYME) announced that its board has authorized a share repurchase plan on Thursday, May 14th, RTT News reports. The company plans to buyback $125.00 million in shares. This buyback authorization authorizes the company to reacquire up to 7% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Stifel Nicolaus increased their price objective on Zymeworks from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. HC Wainwright upped their target price on Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a report on Friday, March 6th. Leerink Partners upped their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Wells Fargo & Company upped their target price on Zymeworks from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Zymeworks Stock Performance

Shares of Zymeworks stock traded down $0.61 during midday trading on Thursday, reaching $23.96. 557,477 shares of the company’s stock traded hands, compared to its average volume of 621,590. The stock has a 50 day moving average of $25.65 and a 200-day moving average of $24.28. The company has a market cap of $1.75 billion, a PE ratio of -17.49 and a beta of 1.20. Zymeworks has a 12 month low of $10.93 and a 12 month high of $29.75.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The firm had revenue of $2.41 million during the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%. On average, equities analysts anticipate that Zymeworks will post 1.64 earnings per share for the current fiscal year.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Zymeworks authorized a new 2026 share repurchase program for up to $125 million, a move that can boost shareholder value and support the stock. Article Title
• Positive Sentiment: The company affirmed liquidity while ending the prior repurchase program after buying back a meaningful amount of stock, reinforcing balance-sheet confidence. Article Title
• Neutral Sentiment: HC Wainwright updated its earnings estimates for Zymeworks, raising FY2026 and Q3 2026 forecasts while trimming Q2 2026 and Q4 2026 estimates; the firm kept a Buy rating and $46 price target.
• Neutral Sentiment: Zymeworks also announced upcoming investor conference appearances, which should help keep the company visible to investors but is not, by itself, a major catalyst. Article Title
• Negative Sentiment: The latest earnings-related coverage noted a mix of progress and pressure, underscoring that the company is still navigating uneven near-term fundamentals despite its longer-term pipeline story. Article Title

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.